Table IV.

Univariate and multivariate analysis on PFS for NSCLC patients with either the exon 19-del or 21-L858R mutation type.

	First-line EGFR-TKIs				First-line chemotherapy				Second-line EGFR-TKIs
		Univariate	Multivariate			Univariate	Multivariate			Univariate	Multivariate
Characteristics	n	P-value	HR (95% CI)	P-value	n	P-value	HR (95% CI)	P-value	n	P-value	HR (95% CI)	P-value
EGFR
19-Del	52	0.018	2.071 (1.120–3.480)	0.006	27	0.105	2.086 (0.988–4.402)	0.054	13	0.090	0.766 (0.275–2.587)	0.843
21-L858R	37				21				14
Age, years
≤60	41	0.629	0.684 (0.418–1.119)	0.131	31	0.688	0.751 (0.378–1.491)	0.423	18	0.288	0.777 (0.195–3.090)	0.720
>60	48				17				9
Sex
Male	41	0.421	0.891 (0.525–1.511)	0.668	28	0.350	1.145 (0.48–2.732)	0.760	15	0.786	1.191 (0.243–5.830)	0.830
Female	48				20				12
Smoking
Ever	22	0.646	1.141 (0.604–2.155)	0.685	17	0.715	0.938 (0.394–2.234)	0.886	10	0.891	1.057 (0.195–5.735)	0.948
Never	67				31				17
Primary site
Left lung	45	0.138	0.721 (0.452–1.151)	0.170	26	0.804	1.143 0.577–2.266	0.701	15	0.105	1.28 0.334–4.893	0.720
Right lung	44				22				12
Drug categories
Gefitinib	58	0.517	0.990 (0.720–1.361)	0.951					16	0.261	0.789 (0.381–1.672)	0.550
Icotinib	17								6
Erlotinib	14								5
Cycles of chemotherapy
≤4					28	0.070	0.444 (0.214–0.921)	0.029	16	0.707	0.905 (0.246–3.329)	0.881
>4					20				11

PFS, progression-free survival; NSCLC, non-small cell lung cancer; CI, confidence interval; HR, hazard ratio; EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors.